Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
Aix-Marseille Université, IRD, APHM, VITROME, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
Int J Antimicrob Agents. 2020 Apr;55(4):105944. doi: 10.1016/j.ijantimicag.2020.105944. Epub 2020 Mar 13.
In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.
2019 年 12 月，一种新型冠状病毒，命名为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2），起源于中国，引发了肺炎疫情爆发，首先在中国武汉地区爆发，然后由于其可能的高传播效率而在全球范围内传播。由于缺乏有效和特异的治疗方法以及需要控制疫情，药物重定位似乎是寻找治疗方法的最佳工具。氯喹、瑞德西韦、洛匹那韦、利巴韦林和利托那韦已显示出体外抑制冠状病毒的疗效。替考拉宁是一种用于治疗葡萄球菌感染的抗生素，先前在人类细胞中显示出抑制中东呼吸综合征冠状病毒（MERS-CoV）病毒生命周期第一阶段的疗效。这种活性对 SARS-CoV-2 是保守的，因此替考拉宁成为治疗这种病毒患者的潜在药物。
